This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Unresectable Advanced Cancer
and you are
between 18 and 75
years old
1
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

MM-398 (also known as PEP02) is nanoliposomal encapsulated irinotecan: the liposomal formulation is designed to extend plasma circulation and to increase accumulation in the tumor through the enhanced permeability and retention (EPR) effect. This study introduces a new concept of combining free and nanoliposomal drugs.

Provided treatments

  • Drug: MM-398
  • Drug: Irinotecan
  • Drug: Leucovorin (LV)
  • Drug: 5-fluorouracile (5-FU)
  • Drug: bevacizumab
  • Drug: MM-398

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02640365. The sponsor of the trial is GERCOR - Multidisciplinary Oncology Cooperative Group and it is looking for 10 volunteers for the current phase.
Official trial title:
A Phase Ib Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer - DOUBLIRI